Ser276 phosphorylation of NF-kB p65 by MSK1 controls SCF expression in inflammation by Reber, Laurent et al.
Ser276 Phosphorylation of NF-kB p65 by MSK1 Controls
SCF Expression in Inflammation
Laurent Reber1, Linda Vermeulen2, Guy Haegeman2, Nelly Frossard1*
1 EA3771, Inflammation and Environment in Asthma, Universite´ Louis Pasteur-Strasbourg-I, Faculte´ de Pharmacie, Illkirch, France, 2 LEGEST, Department of Molecular
Biology, Ghent University, Ghent, Belgium
Abstract
Transcription of the mast cell growth factor SCF (stem cell factor) is upregulated in inflammatory conditions, and this is
dependent upon NF-kB, as well as the MAP kinases p38 and ERK activation. We show here that the MAPK downstream
nuclear kinase MSK1 induces NF-kB p65 Ser276 phosphorylation upon IL-1ß treatment, which was inhibited in cells
transfected with a MSK1 kinase-dead (KD) mutant compared to the WT control. In addition, we show by ChIP experiments
that MSK1 as well as MAPK inhibition abolishes binding of p65, of its coactivator CBP, and of MSK1 itself to the kB intronic
enhancer site of the SCF gene. We show that interaction between NF-kB and CBP is prevented in cells transfected by a p65
S276C mutant. Finally, we demonstrate that both transfections of MSK1-KD and MSK1 siRNA - but not the WT MSK1 or
control siRNA - downregulate the expression of SCF induced by IL-1ß. Our study provides therefore a direct link between
MSK1-mediated phosphorylation of Ser276 p65 of NF-kB, allowing its binding to the SCF intronic enhancer, and
pathophysiological SCF expression in inflammation.
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Introduction
The nuclear factor-kB (NF-kB) family is composed of
homodimers and heterodimers of the Rel family proteins,
including p65 (RelA), c-Rel, RelB, p52 and p50 (for review, see
[1]). The most abundant form of NF-kB is a heterodimer with two
subunits: one p50 and one p65. NF-kB is bound to inhibitory IkB
proteins in the cytoplasm. After stimulation by a variety of stimuli,
NF-kB is released and translocates to the nucleus where it binds to
its coactivators, mainly CBP (CREB-Binding Protein), and
activates expression of pro-inflammatory genes, including the
mast cell growth factor stem cell factor (SCF) [2].
NF-kB is activated by phosphorylation, which plays a key role in
the regulation of its transcriptional activity, and is associated with
nuclear translocation, CBP recruitment and DNA-binding activity
(for review, see [3]). Phosphorylation of p65 occurs on several
serine residues. For instance, upon treatment with TNFa, Ser529
is phosphorylated by casein kinase II [4], Ser536 by the IkB kinase
(IKK) complex [5], Ser311 by protein kinase C (PKC)-f [6], and
Ser276 by both PKA and mitogen- and stress-activated protein
kinase 1 (MSK1) [7,8].
MSK1 has a nuclear localization, and might therefore be an end-
kinase in the inflammatory process involving NF-kB. We therefore
focused our work on the MSK1-induced NF-kB activation as an
approach of the potential role for MSK1 in inflammation. To do so,
we used the SCF gene, to which p65 binds in cells stimulated by the
pro-inflammatory cytokine IL-1ß. In this inflammation model, NF-
kB activation totally controls SCF upregulated expression and the
MAP kinases p38 and ERK, which are the direct activators of the
nuclear kinase MSK1 [9,10], also mediates this upregulation [2].
Results
Binding of the NF-kB complex to the kB site of the SCF
gene
We first show by ChIP experiments that p65 localizes to the kB
intronic enhancer site of the SCF gene upon IL-1b treatment of
human lung fibroblasts in primary culture (Figure 1). We further
show the co-immunoprecipitation of p65, CBP, MSK1, and
Ser10-phosphorylated histone H3 at this site. We further report
that binding of p65, CBP and MSK1 is totally blocked by either
inhibiting the MSK1 upstream kinases, p38 and ERK1/2 by use
of their inhibitors SB202190 (3.5 mM) and PD98059 (20 mM), or
by use of a non-selective MSK1-PKA inhibitor, compound H89
(10 mM). By contrast, phosphorylation of Ser10 histone H3 at the
kB site of the SCF gene was unchanged (Figures 1 and S1). These
results clearly suggest an interaction complex involving p65, CBP
and MSK1 at this kB site dependent on MSK1 activity.
Control of NF-kB activation by MSK1
We used phospho-specific antibodies raised against phospho-
Ser276- and phospho-Ser536-p65 to assess the involvement of
MSK1 and its upstream kinases p38 and ERK on p65
phosphorylation in human lung fibroblasts in primary culture.
IL-1b treatment led to p65 phosphorylation at both serine 536 and
serine 276 in a time-dependent manner. Maximum phosphoryla-
tion was found after 15 and 30 min for Ser536 and Ser276,
respectively (Figure 2A). Inhibitors of the upstream p38 and ERK
MAPK, SB202190 and PD98059, totally abolished the IL-1b-
induced p65 phosphorylation at Ser276 without any effect on
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Ser536 phosphorylation (Figure 2A). As a control, we also
confirmed that these MAPK inhibitors had no effect on IkB
degradation and subsequent NF-kB nuclear translocation
(Figures 2A and S2). The non-selective inhibitor of MSK1-PKA,
compound H89, also blocked the p65 Ser276 phosphorylation
(86% inhibition, figure 2B). To confirm the involvement of MSK1,
we used fibroblasts transfected with a kinase-dead mutant of
MSK1 (MSK1 KD). In fibroblasts transfected with MSK1 KD, a
63% inhibition of the Ser276 phosphorylation induced by IL-1b
was observed, whereas transfection with the MSK1 WT plasmid
had no effect (Figure 2C). This clearly demonstrates that MSK1
controls NF-kB activity through phosphorylation of p65 Ser276.
Control of p65 - CBP interaction by MSK1
Because inhibition of MSK1 impaired CBP recruitment at the
SCF intronic enhancer (Figure 1), we investigated whether this
kinase played a role in the interaction between NF-kB and CBP
during IL-1b treatment. Human lung fibroblasts were transfected
with a His-p65 plasmid. We found that CBP co-immunoprecip-
itated with the His-p65 subunit after IL-1b treatment (Figure 3A).
This interaction was totally blocked when the cells were pre-
incubated with either the MSK1-PKA inhibitor H89 or with
inhibitors of its upstream kinases p38 and ERK, SB202190 and
PD98059. To assess whether the p65 phosphorylation at Ser276
played a role in this interaction, p65-CBP co-immunoprecipitation
was studied in fibroblasts transfected with a S276C His-p65
mutant or its control WT His-p65 plasmid and stimulated with IL-
1ß. Mutation of serine 276 to cysteine totally abolished the p65-
CBP co-immunoprecipitation (Figure 3B). This shows that
phosphorylation of p65 Ser276 by MSK1 mediates NF-kB-CBP
interaction in human lung fibroblasts.
Control of SCF expression by MSK1
We next investigated the physiological consequence of NF-kB
activation by MSK1 on SCF expression. First, we assessed the
effect of MSK1 on SCF promoter activity. Fibroblasts were
transfected with a plasmid encoding the promoter region of the
SCF gene, including exon 1 and the part of intron 1 containing the
kB enhancer site, upstream from a luciferase reporter gene
(pGL3e/SCF), as previously reported [2]. The MSK1-PKA
inhibitor H89 or the MAPK inhibitors had no effect on the
baseline luciferase reporter gene activity (Table S1). IL-1b
increased the SCF promoter activity by 62% at 150 min, the
time of maximum SCF mRNA expression previously reported
[11], while H89 and the inhibitors of the upstream MAPK
SB202190 and PD98059 totally abolished the IL-1b-induced
luciferase reporter activity (figure 4A).
Next, we evaluated the involvement of MSK1 and p65 Ser276
phosphorylation on SCF protein expression. Since H89 is a non-
selective inhibitor of MSK1, we added transfection strategies using
either siRNA against MSK1, MSK1 Kinase-Dead (KD) or S276C
p65 mutant plasmids, as compared to their respective controls.
Baseline levels were not affected by any of the transfections (Table
S2 and S3). Anti-MSK1 siRNA reduced MSK1 protein levels by
60% compared to the irrelevant control siRNA. It inhibited SCF
expression by 51% compared with the control siRNA (Figure 4B).
In addition, transfection of fibroblasts with the MSK1 WT or
KD plasmids led to a 7- and 8-fold MSK1 overexpression,
respectively (Figure S3). MSK1 KD inhibited the SCF expression
by 54% as compared to WT MSK1 or to control expression in
untransfected cells (Figure 4C). Finally, S276C p65 transfection,
inducing a 4-fold protein increase (Figure S3), inhibited SCF
expression by 71% as compared to the p65 WT (figure 4C).
Figure 1. Effect of MAP kinase and MSK1 inhibitors on IL-1b-induced p65, MSK1 and CBP binding to the kB site of the SCF intronic
enhancer. Human lung fibroblasts in culture were pre-incubated for 1 h with a combination of the p38 inhibitor SB202190 (SB; 3.5 mM) and the MEK
inhibitor PD98059 (PD; 20 mM) or with the MSK1-PKA inhibitor H89 (10 mM) and treated with IL-1b (20 U/ml) for 30 min. The ChIP experiment was
performed with anti-p65, MSK1, CBP, phospho-Ser10 histone H3 and control Ig antibodies. Co-immunoprecipitated genomic DNA fragments were
amplified by PCR with SCF intronic enhancer-specific primers. Input reflects the relative amounts of sonicated DNA fragments before
immunoprecipitation. Results are representative of 3 independent experiments performed in fibroblasts from 3 different donors.
doi:10.1371/journal.pone.0004393.g001
MSK1 Controls SCF Expression
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Altogether, our results clearly show that MSK1 controls SCF
protein expression through phosphorylation of p65 at Ser276.
Discussion
We previously reported that the stem cell factor (SCF) gene
activation is regulated through a functional kB enhancer site
originally located in the first intron (+215-GGGAGCTCCC-+225)
of the SCF gene [2]. The first important finding of the present
study is that this kB intronic enhancer site is occupied by NF-kB
and its coactivator CBP upon IL-1b-treatment of primary human
lung fibroblasts, and that MSK1 also co-immunoprecipitates at
this site. This suggests formation of a transcription complex
involving MSK1 at the SCF kB enhancer site in inflammatory
conditions. We additionally clearly show that this is dependent
upon phosphorylation of the Ser276 residue of the p65 subunit of
NF-kB, and that MSK1 is responsible for this phosphorylation.
We demonstrate for the first time that this is a prerequisite for
upregulated SCF expression in inflammation.
Another important finding of this paper is the suppression of
binding of NF-kB, CBP and MSK1 to the SCF intronic enhancer
after inhibition of the MAPKs p38 and ERK. These two MAPKs
are reported to activate MSK1 in inflammatory conditions in cell
lines like HEK293 and L929sA [7]. We additionally show that this
colocalization is suppressed by the non-selective MSK1-PKA
inhibitor H89, indicating that the in vivo occupancy of the SCF
intronic enhancer by NF-kB and CBP is dependent upon MSK1
activation.
Transcriptional activity of NF-kB is controlled by phosphorylation
of p65 at multiple serine residues. Here we show that p65 is
phosphorylated at Ser276 and Ser536 upon IL-1b-treatment in
human lung fibroblasts. However, inhibition of p38 and ERKMAP
kinases had no effect on p65 Ser536 phosphorylation. This contrasts
with p65 Ser536 phosphorylation by the p38 pathway in human
bronchial epithelial BEAS-2B cells after pneumococci stimulation
[12], or by the MEK-ERK pathway in rat vascular smooth muscle
cells in primary culture after angiotensin II treatment [13]. We can
deduce that different pathways may be involved in Ser536
phosphorylation, depending on the stimulus or cell type studied,
which is a new and potently important information.
By contrast, we importantly report that inhibition of the
MAPKs p38 and ERK or of the downstream kinase MSK1 blocks
the phosphorylation of p65 Ser276 induced by IL-1b. This is
consistent with direct p65 phosphorylation by MSK1 at Ser276 by
IL-1b, as was also the case for TNFa, another inflammatory
cytokine, in human HEK293 and murine L929sA cells [7]. This is
also in accordance with the phosphorylation of the equivalent sites
at p50 (Ser337) and c-Rel (Ser267) of the NF-kB protein family
[14] during LPS treatment [15,16,17,18], although phosphoryla-
tion was dependent on a PKAc subunit. Interestingly, PKAc also
leads to p65 Ser276 phosphorylation in response to LPS in murine
70Z/3 pre-B cells [8,19]. The possibility that PKAc might
phosphorylate p65 at Ser276 cannot totally be ruled out by our
studies, since H89 also inhibits PKA [20]. For this reason, we
ascertained the role of MSK1 by transfection of a kinase-dead
Figure 2. Effect of MAP kinase and MSK1 inhibition on IL-1b-induced NF-kB activation. A. Human lung fibroblasts in culture were pre-
incubated for 1 h with a combination of SB202190 (SB; 3.5 mM) and PD98059 (PD; 20 mM) and treated with IL-1b for the indicated time. Western blot
analysis used anti-phospho-Ser276-p65, anti-phospho-Ser536-p65, anti-IkB and anti-p65 antibodies. B. Cells were transfected with 1 mg of pHis-p65
plasmid (WT p65 subunit with a N-terminal His-Tag) and pre-incubated with a combination of SB and PD, or H89 (10 mM) for 1 h before IL-1ß
treatment. C. Cells were co-transfected with His-p65 plasmid and WT or ‘‘kinase-dead’’ (KD) MSK1 plasmid (1 mM), and treated with IL-1b (20 U/ml).
Results are representative of three independent experiments performed in fibroblasts from three different donors.
doi:10.1371/journal.pone.0004393.g002
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mutant of MSK1 (MSK1 KD), inducing inhibition of Ser276
phosphorylation in response to IL-1b, showing an important
reduction (63%) taking into account the transfection efficiency
(70%, data not shown) and the competition obtained (MSK1 KD
vs endogenous MSK1).
Phosphorylation of p65 at Ser276 (as well as the analogous site in
c-Rel) is reported to disrupt the interaction between its C-terminal
and N-terminal regions, thus unmasking an interaction site with the
histone acetyl transferase CBP [8,15]. In the present study, co-
immunoprecipitation experiments demonstrate that p65-CBP inter-
action is directly dependent upon prior p65 phosphorylation at
Ser276 by MSK1. This result conforts the finding that acetylation of
p65 at Lys310 by CBP is secondary to Ser276 phosphorylation [21].
This acetylation of p65 enhances its DNA-binding activity [22].
Similarly, acetylation of p50 and p52 by CBP is linked to DNA-
binding at the iNOS and COX-2 promoter [23,24,25]. Thus we
may postulate that NF-kB and CBP interaction with the SCF
intronic enhancer is a direct consequence of Ser276 phosphoryla-
tion. This is parallel to reports that phosphorylation at Ser337 of the
p50 subunit also controls DNA binding of p50 [16,17]. Interestingly,
the sequence surrounding p50 Ser337 (LRRKS337DLE) is highly
similar to that around p65 Ser276 (LRRPS276DRE) [17]. Moreover,
site-specific phosphorylation is reported to target NF-kB to a
particular subset of genes [14]. Indeed, S276A mutation of p65
inhibits a reporter gene harboring an IL-6-derived kB site
(GGGATTTTCC), while it has no effect when a palindromic kB
site derived from the p52/p100 promoter (GGGAATTCCC) is
concerned. We here report that the GGGAGCTCCC kB site of the
SCF gene is also dependent upon Ser276 p65 phosphorylation, and
that this determines NF-kB binding.
MSK1 also promotes phosphorylation of histone H3 at Ser10
[10,26], depending on the gene, cell type and stimulus. We asked
the question of the role of such MSK1-mediated chromatin
modification in p65 DNA binding to the SCF gene, that would
therefore affect the accessibility of the kB site. However, ChIP
experiments show the absence of modification of H3 Ser10
phosphorylation when MSK1 or its upstream MAPK are
inhibited. Since Duncan and collaborators also reported MSK1
not to phosphorylate histone H3 after TNFa treatment [27], we
may submit that histone H3 phosphorylation is independent of the
MSK1 pathway in inflammation. MSK1-mediated control of p65
binding to the SCF intronic enhancer is thus more likely to be due
to Ser276 phosphorylation rather than chromatin remodelling.
Confirming this hypothesis, we finally demonstrate the direct
involvement of MSK1-mediated p65 Ser276 phosphorylation in
SCF expression. First, blocking the action of MSK1 by either a
kinase-dead MSK1 mutant plasmid or anti-MSK1 siRNA leads to
inhibition of IL-1ß-induced SCF expression. Second, SCF
production is inhibited by mutation of the Ser276 to Cys. Both
serve as the final demonstration that this Ser276 phosphorylation
by MSK1 is a necessary requisite for SCF expression in
inflammation.
In conclusion, we propose a model according to which MSK1
interacts with the enhanceosome and mediates both the binding of
NF-kB to the SCF intronic enhancer and its interaction with its
coactivator CBP (Figure 5). MSK1 may therefore be an interesting
Figure 3. Effect of MSK1-mediated p65 Ser276 phosphorylation on IL-1b-induced p65-CBP interaction. A. Human lung fibroblasts in
culture were transfected with 1 mg of pHis-p65 plasmid (WT p65 subunit with a N-terminal His-Tag), and pre-incubated for 1 h with a combination of
SB202190 (SB; 3.5 mM) and PD98059 (PD; 20 mM), or with H89 (10 mM) and treated with IL-1b (20 U/ml). B. Human lung fibroblasts in culture were
transfected with pHis-p65 or pHis-p65 S276C plasmids (1 mM), and treated with IL-1b (20 U/ml). His-p65 and co-precipitating CBP were revealed by
immunoblotting using anti-p65 and anti-CBP antibodies. IP: immunoprecipitation; IB: immunoblot. Results are representative of three independent
experiments performed in fibroblasts from three different donors.
doi:10.1371/journal.pone.0004393.g003
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Figure 4. Effect of MSK1-mediated p65 Ser276 phosphorylation in IL-1b-induced SCF expression. A. Human lung fibroblasts in culture
were transiently co-transfected with the pGL3e/SCF firefly luciferase construct and a Renilla luciferase construct (pRL-TK) as an internal control. Cells
were pre-incubated for 1 h with a combination of SB202190 (SB; 3.5 mM) and PD98059 (PD; 20 mM) or with H89 (10 mM) and treated with IL-1b (20 U/
ml). After 150 min, cells were harvested for luciferase activity measurement. The results are expressed as the level of pGL3e/SCF constructions’
promoter-driven firefly luciferase expression after correcting for the transfection efficiency by pRL-TK luciferase measurements and represented as a
percentage of control values. B. Fibroblasts were transfected with control and anti-MSK1 siRNA (100 nM), or transfection medium alone (control).
After 48 hours, inhibition of MSK1 with siRNA was controlled by Western blotting in the cell lysate, using anti-MSK1, with anti-b-actin antibodies as a
deposit control. Cells were treated with IL-1b (20 U/ml). SCF protein levels were assessed in the supernatant 5 hours after treatment by ELISA. C.
Fibroblasts were transfected with WT or ‘‘kinase-dead’’ (KD) MSK1 plasmid (1 mg), WT or S276C p65 plasmids or transfection medium alone (control),
and treated with IL-1b (20 U/ml). SCF protein levels were assessed by ELISA in the supernatant obtained 5 hours after treatment. Results are
expressed as percentages of control values of three independent experiments performed in fibroblasts from three different donors.
doi:10.1371/journal.pone.0004393.g004
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Figure 5. Pathway leading to SCF expression in primary human lung fibroblasts upon IL-1b treatment. After treatment with IL-1b, both
p38 and ERK MAPK activate MSK1 which phosphorylates nuclear p65 at Ser276. This leads to binding of NF-kB p65 to the kB site of the SCF intronic
enhancer, and to interaction with the coactivator CBP. Phosphorylation of histone H3 at Ser10 upon IL-1b-treatment is mediated through a MSK1-
independent pathway. IL-1b: interleukin-1b; IL-1R: interleukin-1 receptor; ERK: extracellular signal regulated kinase; MAPK: mitogen-activated protein
kinase; NF-kB: nuclear factor-kB; IkB: inhibitor of NF-kB; MSK1: mitogen- and stress-activated protein kinase 1; CBP: CREB binding protein; H3: histone 3.
doi:10.1371/journal.pone.0004393.g005
MSK1 Controls SCF Expression
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therapeutic target for inflammatory diseases, in view of its central
role in NF-kB activation.
Materials and Methods
Culture of human primary lung fibroblasts
Human lung-derived fibroblasts were obtained by the explant
technique, as described previously [11,28]. Fibroblasts were
cultured in DMEM/F-12 (1:1) medium (Gibco BRL, Cergy
Pontoise, France), supplemented with 10% fetal calf serum (FCS),
penicillin (50 U/ml) and streptomycin (50 mg/ml), and incubated
in a humidified mixture of 95% air and 5% CO2 at 37uC. They
were subsequently split 1:4 at confluence and passaged. Fibroblasts
were used at passage 7.
Cell treatment
At confluence, fibroblasts were starved for 48 h. MAP kinase
pathways were studied with the p38 inhibitor SB202190 (3.5 mM)
and the MEK inhibitor PD98059 (20 mM) (both from Calbio-
chem, La Jolla, CA). MSK1 was inhibited with the compound
H89 (10 mM) (Sigma Chemicals, St. Louis, MO). All these
molecules were incubated for 1 h before IL-1b treatment. Human
recombinant IL-1b (Roche Diagnostics) was added at a final
concentration of 20 U/ml. Control treatments used solvent,
DMSO (0.1%), and had no effect on SCF promoter activity,
p65 phosphorylation or SCF expression.
Plasmids
The pGL3e/SCF reporter plasmid was described previously [2].
pHis-p65 (full-length p65 subunit fused in phase to the N-terminal
histidine Tag), pMSK1-E (named MSK1 WT in this paper, and
coding for human MSK1 C-terminally fused to an E-Tag), pMSK1-
E-D565A (kinase-dead mutant of MSK1, named MSK1 KD in this
paper), pRcRSVp65 (named p65 WT in this paper, coding for the
p65 subunit under the control of the RSV-LTR promoter) and
pRcRSVp65S276C (named p65 S276C in this paper) were all
deposited by Dr. Linda Vermeulen and Prof. Guy Haegeman at the
Belgian Coordinated Collections of Micro-organisms BCCM
plasmid bank. His-tagged forms of the latter two plasmids (His-p65
WT and His-p65S276C in this paper) were constructed by
exchanging the HindIII-Eco91I fragent of the pHis-p65.
Cell transfection
Transient transfection of primary lung fibroblasts was per-
formed with the NucleofectorH kit (Amaxa AG, Germany).
Plasmid DNA (1 mg), control siRNA (100 nM) (sc-37007, Santa
Cruz Biotechnology, Santa Cruz, CA) or MSK1 siRNA (100 nM)
(sc-35977, Santa Cruz Biotechnology) was added to 1.106 cells
suspended in 100 ml of Basic NucleofectorH solution for primary
mammalian fibroblasts. The U-23 program (Amaxa AG, Ger-
many) was selected for optimal density of transfection (70%) and
cell survival (68%), according to the manufacturer’s instructions.
Cells were then plated in 6-well plates and serum-starved for 48 h
before experiments, with medium changed 24 h after transfection.
The green fluorescent protein (GFP) plasmid provided in the
NucleofectorH kit was used to determine the transfection
efficiency, according to the manufacturer’s instructions.
Preparation of cytoplasmic and nuclear extracts
Fibroblasts were rinsed in cold PBS and lysed in a solution
containing 0.6% Nonidet P-40, 10 mM KCl, 10 mM HEPES,
0.1 mM EDTA (all products from Sigma Aldrich), and Com-
pleteTM Mini-EDTA-free protease inhibitor cocktail (Roche
Diagnostics). After centrifugation (30 s, 2000 g), supernatants were
incubated on ice for 5 min. Nuclei were precipitated by
centrifugation (4uC, 3 min, 15000 g), supernatants collected as
cytosolic extracts, and the nuclei resuspended in a solution of 10%
glycerol, 20 mM HEPES, 400 mM NaCl, 1 mM EDTA and
CompleteTM Mini-EDTA-free protease inhibitor cocktail. The
mixture was incubated on ice for one hour, the supernatant
collected after centrifugation for 5 min at 15000 g, and saved as
nuclear extracts.
Immunoprecipitation
Cells were rinsed in cold PBS and lysed in a RIPA buffer (see 1
Western Blotting) or in co-immunoprecipitation buffer (for study
of p65/CBP interaction) containing 200 mM NaCl, 20 mM Tris-
HCl (pH 7.5), 1% Triton X-100, 1 mM DTT and CompleteTM
Mini-EDTA-free protease inhibitor cocktail (1 tablet per 10 ml)
(Roche Diagnostics, all other products from Sigma Aldrich). Cell
lysate was kept on ice for 10 min and centrifuged for 10 min at 14
000 g, 4uC. 1 mg of anti-His-Tag antibody (Invitrogen) was added
to 200 ml of cell lysate and incubated overnight at 4uC. 20 ml of
protein A agarose beads (50% bead slurry) was added for 3 hours
at 4uC. Samples were centrifuged for 30 seconds at 4uC. Pellets
were washed five times with lysis buffer and resuspended in RIPA
buffer. Laemmli buffer was added and samples boiled at 100uC for
5 min. Samples were centrifuged for 1 min at 14 000 g, and
supernatants analysed by Western blotting.
Western Blotting
The fibroblasts were rinsed in cold PBS and lysed in a RIPA
buffer containing 50 mM Tris–HCl pH 7.4, 150 mM NaCl,
1 mM EDTA, 1 mM PMSF, 1% Nonidet P-40, 0.25% sodium
deoxycholate, 1 mM NaF, 1 mM Na3VO4 (all other products
from Sigma Aldrich), and CompleteTM Mini-EDTA-free protease
inhibitor cocktail (Roche Diagnostics). After centrifugation
(30 min, 12 000 g, +4uC), the protein concentration was measured
by the BCA reagents (Sigma Aldrich). Total protein (50 mg) was
subjected to 8-16% SDS-PAGE gel and then blotted onto
nitrocellulose. Immunoblotting used the following antibodies:
rabbit anti-human IkB-a polyclonal antibody (1/1000, Calbio-
chem, La Jolla, CA), mouse anti-human phospho- IkB-a
monoclonal antibody, (1/1000, Ab-1, Oncogene Research
Product, Boston, MA), rabbit anti-human phospho-Ser276 p65
antibody (1/1000, 3037, Cell Signaling Technology, Danvers
MA), rabbit anti-human phospho-Ser536 p65 antibody (1/1000,
3031, Cell Signaling Technology), rabbit anti-human p65
polyclonal antibody (1/200, sc-109, Santa Cruz Biotechnology,
Santa Cruz, CA), rabbit anti-human CBP polyclonal antibody (1/
200, sc-369, Santa Cruz Biotechnology), mouse anti-human b-
actin monoclonal antibody (1/5000, Ab-1, Oncogene Research
Product), goat anti-human MSK1 (1/200, sc-9392, Santa Cruz
Biotechnology. Immunoreactive proteins were detected with
ECLTM reagents (Amersham Biosciences, Orsay, France).
Analysis of reporter gene and SCF expression
Reporter gene assays were carried out as described previously
[2]. SCF production was measured with an ELISA procedure. It
used a capture anti-human SCF monoclonal antibody (clone
13302.6; R&D Systems Europe, Abingdon, UK) and a biotiny-
lated detection anti-human SCF polyclonal antibody (R&D
Systems Europe), revealed by extravidin-horseradish peroxidase
and a 3,39,5,59-tetramethylbenzidine liquid substrate system
(Sigma Chemicals). Standard curves were generated with
recombinant human SCF (R&D Systems Europe) diluted in the
starving medium and were linear from 3.9 to 500 pg/ml.
MSK1 Controls SCF Expression
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Chromatin immunoprecipitation
ChIP assays were performed with a previously described protocol
(Upstate Biotechnology) with modifications. Following treatments,
1.107 adherent fibroblasts per condition were washed with ice-cold
PBS and the cross-linking buffer (100 mM NaCl, 0.5 mM EGTA,
1 mM EDTA, 50 mM Hepes, pH 9). DNA-protein interactions
were then cross-linked for 20 min at room temperature by the
addition of formaldehyde, to a final concentration of 1%. Cross-
linking was stopped by addition of glycine to a final concentration of
125 mM for 5 min. The cell monolayers were rinsed twice with ice-
cold PBS, scraped into conical tubes, and centrifuged at 1500 rpm
for 5 min at room temperature. Pellets were aspirated and
resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM
Tris, pH 8.1), and incubated for 10 min on ice. Samples were
sonicated (4 times, 20 s each, 60%, Vibracell, Bioblock Scientific).
This procedure resulted in DNA fragment sizes of 0.2–1 kb. Samples
were then centrifuged (16 000 g, 10 min, 4uC) into a swinging rotor.
Supernatants were nutated for 1 h at 4uC with 50 ml of 50% slurry
Protein G Agarose/Salmon sperm DNA in SDS lysis buffer
(Upstate, Lake Placid, NY). After centrifugation at 1500 rpm for
5 min, 1 mg of anti-p65, anti-MSK1, anti-CBP, anti-phospho-Ser10
H3 or isotype control antibodies was added to 500 ml aliquots of pre-
cleared chromatin extract and incubated and rotated at 4uC
overnight. 60 ml of protein G agarose/Salmon sperm DNA was
added and the samples incubated and rotated for 1 h at 4uC. After
centrifugation (1000 rpm, 4uC, 1 min), pellets were washed for
5 min with Low Salt immuneComplexWash Buffer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM
NaCl), High Salt Immune Complex Wash Buffer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM
NaCl), LiCl Immune Complex Wash Buffer (0.25 mM LiCl, 1%
IGEPAL-CA630, 1% deoxycholic acid, 1 mMEDTA, 10 mMTris,
pH 8.1) and twice with Tris-EDTA Buffer (10 mMTris-HCl, 1 mM
EDTA, pH 8.0). Histone complexes were eluted by adding 500 ml of
Elution Buffer (1% SDS, 0.1 M NaHCO3). After centrifugation,
20 ml of 5 M NaCl was added to the supernatant and histone-DNA
crosslinks reversed by heating at 65uC overnight. 10 ml of 0.5 M
EDTA, 20 ml of 1 M Tris-HCl, pH 7.5 and 2 ml of 10 mg/ml
Proteinase K were added and the samples placed at 55uC for 3 h.
DNA was phenol-CHCl3-isoamylalcohol (50:49:1)-extracted once,
CHCl3-extracted once and ethanol-precipitated. Pellets were
resuspended in 20 ml of sterile water. PCR reactions (50 ml) were
programmed for 35 cycles with 2 ml of DNA sample and 0.2 mM of
each appropriate primer oligonucleotide. Titrations were performed
to ensure a linear range of amplification. The kB site located in the
first intron of the SCF gene (+215/+225) was amplified with the
PCR primer pairs 59-CTTGCCTGCTTCTCGCCTACCC-39 and
59-CCCCGCATCCTCTTGTCTCACC-39 (position 2111 and
+315).
Supporting Information
Figure S1 Effect of MAP kinase and MSK1 inhibitors on IL-1b-
induced histone H3 phosphorylation. Human lung fibroblasts in
culture were pre-incubated for 1 h with a combination of
SB202190 (SB; 3.5 mM) and PD98059 (PD; 20 mM) or with
H89 (10 mM) and treated with IL-1b for 30 min. The cell lysates
underwent 16% SDS-PAGE electrophoresis and were transferred
onto a nitrocellulose membrane. Western blot analysis used anti-
phospho Ser10 histone H3 antibodies and, as controls, anti-b-actin
antibodies. Results are representative of three independent
experiments performed in fibroblasts from three different donors.
Found at: doi:10.1371/journal.pone.0004393.s001 (0.23 MB
DOC)
Figure S2 Effect of MAPK inhibitors on IkB phosphorylation
and NF-kB nuclear translocation. A. Fibroblasts were pre-treated
for 1 h with the proteasome inhibitor MG132 (MG; 10 mM) alone
(control) or in combination with SB202190 and/or PD98059.
Cells were incubated with IL-1m (20 U/ml) for 0–60 min. Western
blot analysis used anti-phospho IkB antibodies, as well as anti-IkB
antibodies as controls. B. Cells were pre-incubated for 1 h with
SB202190, PD98059 or a combination of both and treated with
IL-1m for 0–30 min. The nuclear and cytoplasmic extracts
underwent 10% SDS-PAGE electrophoresis and were transferred
onto a nitrocellulose membrane. Western blot analysis used anti-
p65, anti m-actin and anti-CBP antibodies. Results are represen-
tative of three independent experiments performed in fibroblasts
from three different donors.
Found at: doi:10.1371/journal.pone.0004393.s002 (1.05 MB
DOC)
Figure S3 Overexpression of WT or KD MSK1 and WT or
S276C p65 plasmids. MSK1 and p65 protein levels were analysed
48h after transfection of lung fibroblasts by western blot. WT or
KD MSK1 plasmids transfection led to MSK1 overexpression (7-
and 8-fold, respectively). WT or S276C p65 plasmids transfection
led both to a 4-fold overexpression of p65. Representative blot and
ratio to m-actin are shown.
Found at: doi:10.1371/journal.pone.0004393.s003 (0.58 MB
DOC)
Table S1 Activity of the pGL3e/SCF plasmid in the presence of
the MAP kinase inhibitors SB202190 and PD98059 or the non
selective MSK1/PKA inhibitor H89. Fibroblasts were co-
transfected with the pGL3e/SCF firefly luciferase construct and
a Renilla luciferase construct (pRL-TK) as an internal control.
Forty-eight hours after transfection, cells were pre-incubated for
1 h with a combination of SB202190 (SB; 3.5 mM) and PD98059
(PD; 20 mM) or with H89 (10 mM) before treatment with IL-1b
(20 U/ml). After 150 min, cells were harvested for luciferase
activity measurement. The results are expressed as the level of
pGL3e/SCF constructions’ promoter-driven firefly luciferase
expression after correcting for the transfection efficiency by
pRL-TK luciferase measurements and represented as a percentage
of control values. Results are means (blocks)6SE mean (bars) of
three independent experiments performed in fibroblasts from
three different donors.
Found at: doi:10.1371/journal.pone.0004393.s004 (0.03 MB
DOC)
Table S2 SCF levels in fibroblasts transfected with control or
anti-MSK1 siRNA. Fibroblasts were transfected with control or
anti-MSK1 siRNA (100 nM) transfection medium alone (‘‘un-
transfected’’). Forty-eight hours after transfection, cells were
treated with IL-1b (20 U/ml). SCF protein levels (pg/ml) were
assessed by ELISA in the supernatant obtained 5 hours after
treatment. Results are means (blocks)6SE mean (bars) of three
independent experiments performed in fibroblasts from three
different donors.
Found at: doi:10.1371/journal.pone.0004393.s005 (0.03 MB
DOC)
Table S3 SCF levels in fibroblasts transfected with KD MSK1
or S276C p65 plasmids and their respective controls. Fibroblasts
were transfected with ‘‘kinase-dead’’ (KD) or WT MSK1 plasmids
(1 mg), S276C or WT p65 plasmids (1 mg) or transfection medium
alone (‘‘untransfected’’). Forty-eight hours after transfection, cells
were treated with IL-1b (20 U/ml). SCF protein levels (pg/ml)
were assessed by ELISA in the supernatant obtained 5 hours after
treatment. Results are means (blocks)6SE mean (bars) of three
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independent experiments performed in fibroblasts from three
different donors.
Found at: doi:10.1371/journal.pone.0004393.s006 (0.03 MB
DOC)
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